S&P Futures
3,923.50 +7.25 (+0.19%) Dow Futures
31,513.00 +26.00 (+0.08%) Nasdaq Futures
12,191.00 +50.50 (+0.42%) Russell 2000 Futures
1,764.10 +2.40 (+0.14%) Crude Oil
107.83 +0.21 (+0.20%) Gold
1,837.20 +6.90 (+0.38%)
Natera, Inc. (NTRA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 38.85 |
| Open | 39.28 |
| Bid | 36.42 x 2200 |
| Ask | 42.00 x 800 |
| Day's Range | 38.21 - 41.80 |
| 52 Week Range | 26.10 - 129.09 |
| Volume | |
| Avg. Volume | 1,506,737 |
| Market Cap | 3.985B |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.89 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 85.20 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NTRA
Related Research
- Natera, Inc.Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, ServiceNow well-poised, electric components on verge of a surge, Illumina's shares have fallen, and Bayer, Carnival, and Kellogg.RatingFair ValueEconomic Moat3 days agoMorningstar
- Simply Wall St.
Insiders rewarded with a US$942k addition on top of their US$5.0m purchase as Natera, Inc. (NASDAQ:NTRA) hits US$3.7b
Natera, Inc. ( NASDAQ:NTRA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
- PR Newswire
Natera Showcases Leadership in Transplantation at ATC 2022 with New Data on its Prospera and Renasight Tests
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has presented data on the clinical utility of the company's Prospera™ and Renasight™ tests in 14 sessions at the American Transplant Congress (ATC) 2022 meeting. This expands on the thirteen peer-reviewed papers that have been published over the last twelve months, demonstrating the strong performance of both assays.
- PR Newswire
Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at the 2022 ASCO Annual Meeting
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the 2022 ASCO® Annual Meeting taking place June 3 – 7, 2022.
